Zacks Research Has Bearish Forecast for JAZZ Q4 Earnings

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – Equities research analysts at Zacks Research decreased their Q4 2026 EPS estimates for Jazz Pharmaceuticals in a research note issued on Thursday, September 24th. Zacks Research analyst Team now anticipates that the specialty pharmaceutical company will earn $5.28 per share for the quarter, down from their prior forecast of $5.29. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $21.61 per share.

JAZZ has been the subject of several other research reports. Stifel Nicolaus set a $275.00 target price on Jazz Pharmaceuticals in a research report on Tuesday, August 4th. Truist Financial raised their price target on Jazz Pharmaceuticals from $264.00 to $281.00 and gave the stock a “buy” rating in a research report on Wednesday, August 26th. JPMorgan Chase & Co. lifted their price objective on Jazz Pharmaceuticals from $265.00 to $276.00 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. The Goldman Sachs Group initiated coverage on Jazz Pharmaceuticals in a research note on Thursday. They issued a “buy” rating and a $337.00 price objective for the company. Finally, Morgan Stanley increased their target price on Jazz Pharmaceuticals from $283.00 to $322.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 26th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $289.37.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $238.28 on Monday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.58 and a current ratio of 1.78. The firm has a market cap of $15.47 billion, a P/E ratio of 16.43, a P/E/G ratio of 0.21 and a beta of 0.36. The firm’s 50 day moving average price is $248.69 and its 200-day moving average price is $228.25. Jazz Pharmaceuticals has a one year low of $125.79 and a one year high of $266.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.18 by ($0.47). Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%.The company had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.11 billion. During the same period last year, the business earned ($8.25) EPS. The company’s quarterly revenue was up 15.5% compared to the same quarter last year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the business’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $250.13, for a total value of $1,500,780.00. Following the completion of the transaction, the director owned 351,875 shares in the company, valued at $88,014,493.75. The trade was a 1.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of the company’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $240.94, for a total value of $289,128.00. Following the sale, the executive vice president directly owned 47,671 shares in the company, valued at $11,485,850.74. This represents a 2.46% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 98,121 shares of company stock valued at $24,443,842 in the last 90 days. Corporate insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. USA Financial Formulas purchased a new stake in Jazz Pharmaceuticals during the 1st quarter worth about $25,000. Ameritas Advisory Services LLC purchased a new position in shares of Jazz Pharmaceuticals in the 2nd quarter valued at about $47,000. Westpac Banking Corp purchased a new position in shares of Jazz Pharmaceuticals in the 1st quarter valued at about $51,000. Root Financial Partners LLC grew its position in shares of Jazz Pharmaceuticals by 42.8% during the first quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company’s stock worth $56,000 after buying an additional 89 shares in the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Jazz Pharmaceuticals during the second quarter worth about $61,000. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a global biopharmaceutical company focused on developing and commercializing medicines for disorders in neuroscience and oncology. The company concentrates on conditions with significant unmet medical needs, including sleep disorders, epilepsy, rare diseases and certain cancers.

Its neuroscience portfolio includes Xywav and Xyrem, oxybate-based treatments for narcolepsy, with Xywav also indicated for idiopathic hypersomnia in adults. Jazz also markets Epidiolex in the United States, known as Epidyolex in some international markets, a cannabidiol-based medicine for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex.

In oncology, Jazz’s products include Rylaze, an asparaginase therapy used as part of treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca, used for certain patients with metastatic small cell lung cancer; and Vyxeos, a chemotherapy formulation for certain cases of newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes.